argenx posted $1.3 bn global product net sales in Q1 2026, a 63% YoY increase from $790 m.
Adjusted earnings per share rose to $5.52 versus $2.58 a year earlier, while net profit jumped 116% to $366 m.
Operating profit climbed to $394 m from $139 m, with operating expenses up to $919 m driven by R&D $443 m and SG&A $355 m.
CEO Karen Massey highlighted continued Vyvgart growth, noting a pending FDA decision for label expansion and a PDUFA target date of May 10 2026.